2021 Q4
- Chief Scientific Officer presented at CTAD 2021 FDA breakthrough software medical device that could transform Alzheimer’s space
- CEO honored among 25 top women leaders in biotech
- Launched Medscape content partnership
2021 Q3
- – Chief Medical and Technology Officer presented to neurology community at ANA2021 about technology in development to address dementia and MCI
- Darmiyan recognized as UCSF Award finalist – hospital diagnostics category
- Mounted brain health content series with GetSetup adult learning platform featuring Chief Medical and Technology Officer, yielding record registration levels
2021 Q2
- – FDA: BrainSee Novel Software Is Breakthrough For Noninvasive Detection And Monitoring Of Alzheimer’s Disease At The Early Stage Of Mild Cognitive Impairment
- Presented to the neuroradiology community in ASNR 2021
2021 Q1
Darmiyan developed a suite of cutting-edge, novel tools for clinics and clinical trials
2020 Q4
Darmiyan presented validation results in CTAD 2020
2020 Q2 & Q3
- Darmiyan CEO was selected by Fortune 40 under 40
- Darmiyan’s core technology, BrainSee, was blind-tested and validated by independent third-party investigators in the US and Canada. See press release here.
2020 Q1
- – Pharma giant Eisai led a $6M round in Darmiyan
- US patent was published
2019 Q4
- Blind testing validation results are published in BioRxiv, and established ~ 90% accuracy in the diagnosis of MCI and AD and 5-year prognosis of MCI
- Started POC study with Banner Alzheimer’s Institute, focused on early detection of AD at preclinical (presymptomatic) stage
- Presented at CTAD (Clinical Trials on Alzheimer’s Disease) 2019 conference, San Diego
- Presented at Washington Longevity Summit, Washington DC
- Press room in Washington DC
2019 Q3
- – Released BrainSee version 1.0
- Tested the product on 3170 brain scans (Normal, MCI, AD) and 411 longitudinal MCI cases with 5-year follow up
- Signed partnership with Mary Furlong & Associates
- Podcast with Dr. Allison Sekuler, Mary Furlong and Darmiyan CTO Dr. Kaveh Vejdani recorded in UC Berkeley
- Patents filed in Europe and Asia
2019 Q2
- – Developed a fully automated pipeline for image processing and data analysis
- Featured article, Alzheimer’s disease noise or signal, in response to Bill Gates
2019 Q1
- – Met with FDA in Washington to discuss regulatory strategy
- Partnership signed with CABHI (Center for Aging and Brain Health Innovation) partner sites Baycrest Institute, University Health Network (UHN) and Hamilton Health Sciences
- Rresented at CABHI’s What’s Next Canada meeting in Toronto and won the 2019 CABHI Innovation Award
- Toronto office was opened to explore business development opportunities in Canada
2018 Q4
- – Presented at TEDMED Hive, Palm Springs, CA
- FDA Q-sub (pre-submission) application sent
2018 Q3
- Panelist at MedTech Conference, Neurotechnology section, Philadelphia, PA
- Moved to a new office space in downtown San Francisco, CA
2018 Q2
- – Won a CABHI Industry Innovation (I2P2) award for CAN $500K
- PCT patents filed and US patent application was fast-tracked – Finalist for AI for Good $500K prize
- Signed partnership agreement with Boston University
2018 Q1
- Image analysis and machine learning pipelines designed and developed
- Signed partnership agreement with Banner Alzheimer’s Institute
2017 Q4
- Graduated from SkyDeck UC Berkeley
- Moved to new office space in Emeryville, CA, team expanded to 6 FTE
- Non-provisional US patent filed
2017 Q3
- Graduated from Y-Combinator program
- Raised seed financing
- VentureBeat news published
- Hacker News article released
- WSGR engaged as IP legal counsel
2017 Q2
- Won Amgen-QB3/MBC Biolabs Golden Ticket Award
- Accepted to Y-Combinator S17 Batch
- Accepted to SkyDeck UC Berkeley
2017 Q2
- Won Amgen-QB3/MBC Biolabs Golden Ticket Award
- Accepted to Y-Combinator S17 Batch
- Accepted to SkyDeck UC Berkeley
2017 Q1
- Product designed and strategy identified
- Prototype developed and got preliminary results
2016
- Paul Hastings LLP engaged as legal counsel
- Incorporated in Delaware (Sep)
- Registered in California and raised pre-seed financing